Terray Therapeutics

Terray Therapeutics is revolutionizing small molecule drug discovery and development through a sophisticated integration of ultra-high throughput experimentation, generative AI, biology, medicinal chemistry, automation, and nanotechnology. The company's platform uniquely blends experimentation and computation to improve the cost, speed, and success rate of drug discovery. Terray's experimental dataset includes more than two billion unique target-ligand binding measurements, growing by 300 million new measurements every month. Their approach involves a closed-loop iteration process, with a design-make-test-analyze cycle taking less than a month per target. This enables intelligent exploration of chemical space, experimentally measuring millions of molecules at a time. Terray's tNova platform, a generative AI model, is designed to dramatically improve the success rate of small-molecule development. The company has built what it claims to be the world's largest chemistry dataset, measuring more than 5 billion target-ligand interactions in the past three years. Terray's internal pipeline focuses on immunology, and they also apply their platform to a wide range of challenging targets and therapeutic areas through partnerships with large pharma and biotech companies.